On Tuesday, Following Stocks were among the “Top 50 Gainers” of U.S. Stock Market: General Cable Corp. (NYSE:BGC), Arcos Dorados Holdings Inc. Cla (NYSE:ARCO), NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY), Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH)
General Cable Corp. (NYSE:BGC), with shares surged 21.27%, closed at $17.73.
Arcos Dorados Holdings Inc. Cla (NYSE:ARCO), with shares jumped 19.86%, settled at $5.07.
NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY), with shares climbed 19.09%, and closed at $0.63.
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH), soared 18.70%, and closed at $4.76.
Latest NEWS regarding these Stocks are depicted underneath:
General Cable Corp. (NYSE:BGC)
According to Bloomberg, the world’s largest cable maker, Prysmian (PRYMY), is considering an attainment of its rival to raise its North American market share.
Although there have not been any talks between the two companies, Prysmian has held preliminary discussions on a potential bid for General Cable with financial advisers, Bloomberg added. On the other hand, according to Reuters’ report, A spokesman for Prysmian said the corporation is evaluating “all growth options” and has no talks ongoing with General Cable.
General Cable Corporation designs, develops, manufactures, markets, and distributes copper, aluminum, and fiber optic wire and cable products for the energy, industrial, construction, and specialty and communications markets worldwide.
Arcos Dorados Holdings Inc. Cla (NYSE:ARCO)
On Tuesday, Arcos Dorados Holdings Inc. Cla (ARCO), Latin America’s largest restaurant chain and the world’s largest McDonald’s franchisee, stated unaudited results for the fourth quarter and audited results for the full year ended December 31, 2014.
Fourth Quarter 2014 Key Results:
- Merged proceeds were $913.6 million, a 12.7% decline as compared to the fourth quarter of 2013. On an organic basis and not including Venezuela, merged proceeds grew 11.1%.
- Systemwide comparable sales raised by 15.4% year-over-year.
- As stated General and Administrative expenses (G&A) as a percentage of proceeds declined by 44 basis points as compared to the same period last year.
- Adjusted EBITDA was $93.3 million, or 20.9% lower year-over-year. Organic Adjusted EBITDA not including Venezuela, reduced by 4.6% as compared to the preceding year quarter.
- Stated net revenue of $10.0 million, contrast to net revenue of $32.1 million in the year-ago period, mainly due to lower operating results and higher foreign exchange losses.
Full Year 2014 Key Results:
- Merged proceeds were $3.7 billion in 2014, a 9.5% decline as compared to 2013. On an organic basis and not including Venezuela, merged proceeds grew 9.6% in the year.
- Systemwide comparable sales raised by 10.0% year-over-year.
- As stated G&A as a percentage of proceeds declined by 43 basis points as compared to 2013.
- Adjusted EBITDA was $251.7 million, or 26.9% lower year-over-year. Organic Adjusted EBITDA not including Venezuela, raised by 0.6% as compared to the preceding year.
- Stated a net loss of $109.3 million, contrast to net revenue of $53.9 million one year ago, mostly the result of the influences from the transitions to SICAD and SICAD II in Venezuela.
- Capital expenditures for the year totaled $169.8 million, which comprised of 82 new restaurant openings and brought the overall restaurant count to 2,121 at year end.
Arcos Dorados is the world’s largest McDonald’s franchisee in terms of systemwide sales and number of restaurants, operating the largest quick service restaurant (“QSR”) chain in Latin America and the Caribbean. It has the exclusive right to own, operate and grant franchises of McDonald’s restaurants in 20 Latin American and Caribbean countries and territories, counting Argentina, Aruba, Brazil, Chile, Colombia, Costa Rica, Curaçao, Ecuador, French Guyana, Guadeloupe, Martinique, Mexico, Panama, Peru, Puerto Rico, St. Croix, St. Thomas, Trinidad & Tobago, Uruguay and Venezuela.
NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY)
On Tuesday, The National Necrotizing Fasciitis Foundation (NNFF) recently declared the NNFF has named NeutroPhase®, a wound cleanser made by NovaBay Pharmaceuticals, Inc. (NBY), the official wound cleanser of the NNFF.
The NNFF has already teamed up with NovaBay and NovaBay’s partner China Pioneer Pharma Holdings Ltd to offer NeutroPhase free of charge anywhere in the world to patients with ‘flesh-eating’ disease, or necrotizing fasciitis. NovaBay has also signed distribution contracts with Shin-Poong Pharma in South Korea, the Biopharm Group in Egypt and the Middle East, and Alpha Pharma LLC in the Ukraine.
In addition, the NNFF connects patients and their families to doctors who have pioneered the use of NeutroPhase to treat the disease, such as Dr. John Crew, director of the Advanced Wound Care Center at Seton Medical Center in Daly City, Calif, and Dr. Anibal Gauto, Medical Director of the Wound Care Center at Eisenhower Medical Center in Rancho Mirage, Calif.
By naming NeutroPhase the official wound cleanser of the NNFF, Roemmele hopes to bring more attention to the successful results of doctors like Dr. Crew and Dr. Gauto. “We can now direct patients to a new, life-saving treatment—and to a growing number of doctors who are practiced at using the treatment,” she said.
NovaBay Pharmaceuticals, Inc., a clinical-stage biotechnology corporation, focuses on developing product candidates for the therapeutic needs of anti-infective market.
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH)
On Tuesday, Anthera Pharmaceuticals, Inc. (ANTH), declared that it intends to offer and sell shares of its ordinary stock in an underwritten public offering. The Corporation anticipates to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of ordinary stock offered in the public offering to cover over-allotments, if any. The Corporation intends to use the net proceeds from the offering for clinical research and development and general corporate purposes. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be accomplished, or as to the actual size or terms of the offering.
Piper Jaffray & Co. is acting as sole underwriter in the offering.
Anthera Pharmaceuticals is a biopharmaceutical corporation focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
